{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Study toxicity will be measured on an ongoing basis, no less then once per 28-day cycle.","groups":[{"description":"Bendamustine: On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\\^2, and then to 60 mg/m\\^2 bendamustine on days 1 and 4 if ANC is not \\>1 x 10\\^9/L and platelets are not \\>50 x 10\\^9/L on day 1 of each cycle.\n\nPatients will be treated until disease progression after at least one cycle of treatment.\n\nBortezomib: On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\\^2 followed by bendamustine given at 90 mg/m\\^2. Patients will be dose reduced to 75 mg/m\\^2, and then to 60 mg/m\\^2 bendamustine on days 1 and 4 if ANC is not \\>1 x 10\\^9/L and platelets are not \\>50 x 10\\^9/L on day 1 of each cycle.\n\nPatients will be treated until disease progression after at least one cycle of treatment.","id":"OG000","title":"Bortezomib and Bendamustine"}],"populationDescription":"Participant data was not analyzed because PI left institution. Data were not available for analysis.","reportingStatus":"POSTED","timeFrame":"Every 4 weeks.","title":"Toxicity of This Regimen.","type":"SECONDARY"}